Key highlights
- Genmab discontinues acasunlimab development after portfolio review.
- Focus shifts to EPKINLY, petosemtamab, and Rina-S in late-stage pipeline.
- Decision aligns with Genmab's capital allocation strategy.
- No impact on Genmab's 2025 financial guidance.
Portfolio Update
Genmab has decided to halt the clinical development of acasunlimab. This decision follows a strategic review of its late-stage portfolio, focusing on projects with the highest potential impact.
Strategic Focus
The company will now concentrate resources on advancing EPKINLY, petosemtamab, and Rina-S, which are in late-stage development. This move is part of Genmab's disciplined approach to portfolio prioritization and capital allocation.
Financial Guidance
Genmab confirms that this decision will not affect its full-year 2025 financial guidance, maintaining its financial outlook despite the shift in focus.
